Artificial macrocycles as IL-17A/IL-17RA antagonistsWang, W., Groves, M. R. & Domling, A., Jan-2018, In : MedChemCommun. 9, 1, p. 22-26 5 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Interleukin 17(A) is a pro-inflammatory cytokine involved in several auto-immune and inflammatory diseases. Current antagonists against IL-17(A) or its receptor (IL-17RA) that show efficacy in clinical trials are monoclonal antibodies (mAbs). However, recently designed artificial macrocycles are potent IL-17A/IL-17RA antagonists. Based on co-crystal structures, a better understanding of the biological activity and SAR of the macrocycles has been gained, demonstrating that they can compete with mAbs for difficult targets such as PPIs.
|Number of pages||5|
|Publication status||Published - Jan-2018|
- DRUG DISCOVERY, BINDING-SITE, T-CELLS, INTERLEUKIN-17, RECEPTOR, INFLAMMATION, IL-17A, COMBINATION, AUTOIMMUNE, CYTOKINES